GLP-1 non-peptide pipeline market seen jumping to $14.39 billion by 2030

The market for non-peptide small molecule GLP-1 multi-indication therapies is projected to rise from $3.68 billion in 2025 to $14.39 billion by 2030, according to The Business Research Company. Growth is being driven by demand for oral obesity and diabetes treatments, with North America currently the largest market and Asia-Pacific expected to grow fastest.

Why it matters: - Non-peptide small molecule GLP-1 drugs could widen access to metabolic treatments by offering oral alternatives to injectable peptide therapies. - The pipeline targets obesity, type 2 diabetes and other GLP-1-linked conditions, which are major and growing global health burdens. - Oral delivery may improve convenience and adherence compared with injection-based regimens.

What happened: - The Business Research Company published its Non-Peptide Small Molecule Glucagon-Like Peptide (GLP)-1 Multi-Indication Pipeline Global Market Report 2026. - The report estimates the market at $3.68 billion in 2025 and $4.82 billion in 2026. - The report projects the market will reach $14.39 billion by 2030. - The report says the 2025-2026 growth rate is 31.2%, with a 31.4% CAGR forecast through 2030. - The report was released July 25, 2026, from London. - Download a free sample or view the full report.

The details: - Non-peptide small molecule GLP-1 therapies are orally available compounds designed to activate or modulate GLP-1 receptor pathways. - These therapies aim to mimic metabolic effects without using peptide structures that typically require injection. - The report ties market growth to rising obesity and type 2 diabetes rates, oral bioavailability advances and the high cost and long timelines of peptide drug development. - The report also cites first-generation GLP-1 receptor agonist approvals as a factor shaping the market. - It highlights growth in oral small molecule GLP-1 agonist pipelines, broader multi-indication metabolic treatment use, non-peptide receptor modulation technology and pharmaceutical-biotech partnerships. - The report expects more combination treatments, small molecule drug discovery advances and new oral bioavailability technologies for peptide-free metabolic drugs. - The report says obesity is a key demand driver because excess weight raises the risk of diabetes, cardiovascular disease and hypertension. - The report links obesity growth to diets high in processed, calorie-dense and sugary foods, plus sedentary lifestyles. - UK data cited in the report showed 64.5% of adults in England were overweight or obese in 2023-2024, up from 64.0% a year earlier.

Between the lines: - The forecast suggests investors and drug developers are betting that the biggest constraint on GLP-1 expansion is no longer efficacy alone, but delivery format and scalability. - The emphasis on oral drugs and combination therapy points to a market moving from niche innovation toward broader chronic-care use. - North America’s current lead and Asia-Pacific’s faster growth signal that commercial demand is both mature and still expanding geographically. - The report’s heavy use of pipeline and forecast language means the figures reflect expected development, not approved-product sales.

What's next: - The report expects accelerated development of oral non-peptide GLP-1 receptor agonists through 2030. - The market is likely to see more therapies aimed at both obesity and diabetes. - Strategic partnerships among drugmakers and biotech companies are expected to continue. - The Business Research Company says its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics and updated trend analysis. - The report says North America held the largest market share in 2025, while Asia-Pacific is expected to be the fastest-growing region over the forecast period. - The regional analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Oral, non-peptide GLP-1 drugs are emerging as a high-growth bet in metabolic medicine, with demand driven by obesity, diabetes and the push for easier-to-use treatments.